Erratum: Expression of Concern: Identification of the Sites of Tau Hyperphosphorylation and Activation of Tau Kinases in Synucleinopathies and Alzheimer’s Diseases(PLoS ONE (2023) 8:9 (e75025) DOI: 10.1371/journal.pone.0075025);Identification of the Sites of Tau Hyperphosphorylation and Activation of Tau Kinases in Synucleinopathies and Alzheimer's Diseases

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Duka, Valeriy ^a   Lee, Jae Hoon ^a   Credle, Joel ^a   Wills, Jonathan ^a   Oaks, Adam ^a   Smolinsky, Ciaran ^a   Shah, Ketul ^a   Mash, Deborah C ^b   Masliah, Eliezer ^c   Sidhu, Anita ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; BIOLOGICAL MARKER; EPITOPE; GAMMA SYNUCLEIN; TAU KINASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING SITE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ENZYME ACTIVATION; ENZYME ANALYSIS; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; PARKINSON DISEASE; PROLINE RICH PROTEIN DOMAIN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STRIATE CORTEX;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; BRAIN; DEMENTIA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOENZYME TECHNIQUES; LEWY BODIES; PARKINSON DISEASE; PHOSPHORYLATION; TAU PROTEINS;

EID: 84884478145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0295638     Document Type: Erratum

References (37)

1. Hanger DP, Anderton BH, Noble W, (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15: 112-119. doi:10.1016/j.molmed.2009.01.003. PubMed: 19246243.
2. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I, (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7(8):: 656-664.
3. Lippens G, Amniai L, Wieruszeski JM, Sillen A, Leroy A, et al. (2012) Towards understanding the phosphorylation code of tau. Biochem Soc Trans 40(4):: 698-703. doi:10.1042/BST20120050. PubMed: 22817719. Review.
4. Goedert M, Spillantini MG, (1998) Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry 3: 462-465. doi:10.1038/sj.mp.4000458. PubMed: 9857966.
5. Dauer W, Przedborski S, (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909. doi:10.1016/S0896-6273(03)00568-3. PubMed: 12971891.
6. Jellinger KA, (2012) Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med 16(6):: 1166-1183. doi:10.1111/j.1582-4934.2011.01507.x. PubMed: 22176890.
7. Gilley J, Adalbert R, Coleman MP, (2011) Modelling early responses to neurodegenerative mutations in mice. Biochem Soc Trans 39(4):: 933-938. doi:10.1042/BST0390933. PubMed: 21787326.
8. Shahpasand K, (2012) Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J Neurosci 32(7):: 2430-2441. doi:10.1523/JNEUROSCI.5927-11.2012. PubMed: 22396417.
9. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, et al. (2010) Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285: 30851-30860. doi:10.1074/jbc.M110.110957. PubMed: 20663882.
10. Lovestone S, Reynolds CH, (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324. doi:10.1016/S0306-4522(96)00577-5. PubMed: 9145789.
11. Ballatore C, Lee VM, Trojanowski JQ, (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8: 663-672. doi:10.1038/nrn2194. PubMed: 17684513.
12. Muntané G, Dalfó E, Martinez A, Ferrer I, (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 152: 913-923. doi:10.1016/j.neuroscience.2008.01.030. PubMed: 18343584.
13. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 225: 210-218. doi:10.1016/j.expneurol.2010.06.017. PubMed: 20599975.
14. Kaul T, Credle J, Haggerty T, Oaks AW, Masliah E, et al. (2011) Region-specific tauopathic changes in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neurosci 12: 79.
15. Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, et al. (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 20: 2302-2312. doi:10.1096/fj.06-6092com. PubMed: 17077307.
16. Duka T, Sidhu A, (2006) The neurotoxin, MPP+, induces hyperphosphorylation of Tau in the presence of alpha-Synuclein in SH-SY5Y neuroblastoma cells. Neurotox Res 10: 1-10. doi:10.1007/BF03033329. PubMed: 17000465.
17. Duka T, Duka V, Joyce JN, Sidhu A, (2009) Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 23: 2820-2830. doi:10.1096/fj.08-120410. PubMed: 19369384.
18. Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar J, King LT, et al. (2006) Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. Chemmedchem 1: 256-266. doi:10.1002/cmdc.200500039. PubMed: 16892358.
19. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, et al. (2011) Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's. Eur J Neurosci: pp. 1-13.
20. Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, et al. (2011) Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease. PLOS ONE 6(3):: e17953. doi:10.1371/journal.pone.0017953. PubMed: 21445308.
21. Wills J, Credle J, Oaks AW, Duka V, Lee JH, et al. (2012) Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLOS ONE. 7(1):: e30745. doi:10.1371/journal.pone.0030745. PubMed: 22292029. Epub(2012) Jan 23. PubMed: 22292029.
22. Papapetropoulos S, Lieberman A, Gonzalez J, Mash DC, (2005) Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand 111(6):: 353-359. doi:10.1111/j.1600-0404.2005.00411.x. PubMed: 15876335.
23. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, et al. (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and models of alpha-synucleinopathy. PLOS ONE 5(2):: e9313. doi:10.1371/journal.pone.0009313. PubMed: 20174468.
24. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR, (2000) Tau proteinisoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-130.
25. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E, (2001) beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 32(2):: 213-223. doi:10.1016/S0896-6273(01)00462-7. PubMed: 11683992.
26. Hashimoto M, Bar-On P, Ho G, Takenouchi T, Rockenstein E, et al. (2004) Beta-synuclein regulates Akt activity in neuronal cells A possible mechanism for neuroprotection in Parkinson's disease. J Biol Chem 279(22):: 23622-9.38.
27. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, et al. (2009) Gamma-synucleinopathy: neurodegeneration associated with overexpression of mouse protein. Hum Mol Genet 18(10):: 1779-1794. doi:10.1093/hmg/ddp090. PubMed: 19246516.
28. Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, et al. (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 13650-13655. doi:10.1073/pnas.2232515100. PubMed: 14595022. doi:10.1073/pnas.2232515100 PubMed: 14595022.
29. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, et al. (1999) alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 274: 25481-25489. doi:10.1074/jbc.274.36.25481. PubMed: 10464279.
30. Qureshi HY, Paudel HK, (2011) Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP] and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem 286: 5055-5068. doi:10.1074/jbc.M110.178905. PubMed: 21127069.
31. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, et al. (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198(5):: 351-356. doi:10.1192/bjp.bp.110.080044. PubMed: 21525519.
32. Zhu X, Lee HG, Raina AK, Perry G, Smith MA, (2002) The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11: 270-281. doi:10.1159/000067426. PubMed: 12566928.
33. Kins S, Kurosinski P, Nitsch RM, Götz J, (2003) Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 163(3):: 833-843. doi:10.1016/S0002-9440(10)63444-X. PubMed: 12937125.
34. Echeverria V, Ducatenzeiler A, Dowd E, Jänne J, Grant SM, et al. (2004) Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience 129: 583-592. doi:10.1016/j.neuroscience.2004.07.036. PubMed: 15541880.
35. Ando K, Uemura K, Kuzuya A, Maesako M, Asada-Utsugi M, et al. (2011) N-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease. J Biol Chem 286: 7619-7628. doi:10.1074/jbc.M110.158477. PubMed: 21177868.
36. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH, (1998) New phosphorylation sites identified in hyperphosphorylated tau [paired helical filament-tau] from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71: 2465-2476. PubMed: 9832145.
37. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, et al. (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9(4):: 397-405. doi:10.2174/156720512800492503. PubMed: 22272619.